Novo Nordisk Reports Results of Refixia (nonacog beta pegol) in Two P-III Studies for Hemophilia B in Children

 Novo Nordisk Reports Results of Refixia (nonacog beta pegol) in Two P-III Studies for Hemophilia B in Children

Novo Nordisk Reports Results of Refixia (nonacog beta pegol) in Two P-III Studies for Hemophilia B in Children

Shots:

  • The two P-III studies include Paradigm5 & 6. Paradigm5 involves assessing of Refixia (40 IU/kg, qw) in 25 children with hemophilia B aged ≤12 yrs. resulted in low bleeding rates with 20% bleed free patients and 64% with no spontaneous bleeds. No children developed inhibitory Ab & no new safety signals are observed
  • The P-III Paradigm6 study involves assessing of Refixia in male with FIX ≤2%, prior untreated/with ≤3 EDs to FIX-containing products aged <6 yrs. resulted in low bleeding rates and good bleed resolution with median ABRs of 0.0 for overall, spontaneous and traumatic bleeds + 6.1% patients developed inhibitory Ab
  • Refixia (N9-GP) is an extended half-life factor IX molecule for replacement therapy indicated to treat and prevent bleeding in patients with haemophilia B and has received EMA’s approval in Jun’2017

Click here to read full press release/ article | Ref: Novo Nordisk | Image: Novo Nordisk

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post